Chlorpromazine equivalent doses for the newer atypical antipsychotics

被引:1821
作者
Woods, SW [1 ]
机构
[1] Yale Univ, Sch Med, Dept Psychiat, Connecticut Mental Hlth Ctr, New Haven, CT 06519 USA
关键词
D O I
10.4088/JCP.v64n0607
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Several clinical and research applications require an estimation of therapeutic dose equivalence across antipsychotic medications. Since the advent of the newer atypical antipsychotics, new dose equivalent estimations have been needed. Method: The reported minimum effective dose was identified for each newer atypical antipsychotic medication and for haloperidol across all available fixed-dose placebo-controlled studies. Reported minimum effective dose equivalence ratios to haloperidol were then converted to chlorpromazine equivalents using the "2 mg of haloperidol equals 100 mg of chlorpromazine" convention. Data Sources and Study Selection: To identify the fixed-dose studies, the following sources were searched until June 2002: MEDLINE, the bibliographies of identified reports, published meta-analyses and reviews, Cochrane reviews, Freedom of Information Act material available from the Food and Drug Administration, and abstracts from several scientific meetings from 1997 to 2002. Results: Doses equivalent to 100 mg/day of chlorpromazine were 2 mg/day for risperidone, 5 mg/day for olanzapine, 75 mg/day for quetiapine, 60 mg/day for ziprasidone, and 7.5 mg/day for aripiprazole. Conclusion: These equivalency estimates may be useful for clinical and research purposes. The source of the dose equivalency estimation is evidence-based and consistent across medication.
引用
收藏
页码:663 / 667
页数:7
相关论文
共 39 条
[1]   Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo [J].
Arvanitis, LA ;
Miller, BG ;
Borison, RL ;
Pitts, WM ;
Sharif, ZA ;
Hamner, MB ;
Herz, MI ;
True, JE ;
Velligan, D ;
Knesevich, MA ;
Small, J ;
Steinbook, R ;
Hertzman, M ;
Keck, PE ;
Newcomer, JW ;
Grace, J ;
Rotrosen, J ;
Tandon, R ;
Dott, SG ;
Ferguson, JM ;
Addington, DEN ;
MacEwan, GW ;
Nair, VNP ;
Shriqui, CL ;
Williams, R ;
Daniel, DG ;
Shehi, GM ;
Patterson, WM ;
Merideth, CH .
BIOLOGICAL PSYCHIATRY, 1997, 42 (04) :233-246
[2]  
BAGNALL A, 2001, COCHRANE LIB
[3]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[4]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[5]   Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics [J].
Bech, P ;
Peuskens, JCJR ;
Marder, SR ;
Chouinard, G ;
Hoybergs, OJ ;
Huttunen, MO ;
Blin, O ;
Claus, A .
EUROPEAN PSYCHIATRY, 1998, 13 (06) :310-314
[6]  
CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P149
[7]   CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA - BEHAVIORAL DOSE-RESPONSE RELATIONSHIPS [J].
CLARK, ML ;
RAMSEY, HR ;
RAGLAND, RE ;
RAHHAL, DK ;
SERAFETI.EA ;
COSTILOE, JP .
PSYCHOPHARMACOLOGIA, 1970, 18 (03) :260-&
[8]   A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia [J].
Cooper, SJ ;
Tweed, J ;
Raniwalla, J ;
Butler, A ;
Welch, C .
ACTA PSYCHIATRICA SCANDINAVICA, 2000, 101 (03) :218-225
[9]   Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial [J].
Daniel, DG ;
Zimbroff, DL ;
Potkin, SG ;
Reeves, KR ;
Harrigan, EP ;
Lakshminarayanan, M .
NEUROPSYCHOPHARMACOLOGY, 1999, 20 (05) :491-505
[10]   DOSE EQUIVALENCE OF ANTI-PSYCHOTIC DRUGS [J].
DAVIS, JM .
JOURNAL OF PSYCHIATRIC RESEARCH, 1974, 11 :65-69